Progressive Multifocal Leukoencephalopathy News and Research

RSS
Four genetic mutations linked to progressive multifocal leukoencephalopathy

Four genetic mutations linked to progressive multifocal leukoencephalopathy

Newly identified brain molecule orchestrates the immune system's responses to Alzheimer's and MS

Newly identified brain molecule orchestrates the immune system's responses to Alzheimer's and MS

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Study of MS patients shows 18% were given wrong diagnoses

Study of MS patients shows 18% were given wrong diagnoses

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

FDA approves new drug to treat MS in pediatric patients

FDA approves new drug to treat MS in pediatric patients

Extending dosing intervals makes common multiple sclerosis drug safer to use

Extending dosing intervals makes common multiple sclerosis drug safer to use

TSRI scientists shed light on molecular workings of MS drug

TSRI scientists shed light on molecular workings of MS drug

Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Rituximab outperforms fingolimod after natalizumab switch

Rituximab outperforms fingolimod after natalizumab switch

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab shows relapse prevention benefits over fingolimod in MS

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Researchers reveal potential new treatment methods for fatal brain disease

Researchers reveal potential new treatment methods for fatal brain disease

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.